551 related articles for article (PubMed ID: 29202477)
1. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
Chen L; Alexe G; Dharia NV; Ross L; Iniguez AB; Conway AS; Wang EJ; Veschi V; Lam N; Qi J; Gustafson WC; Nasholm N; Vazquez F; Weir BA; Cowley GS; Ali LD; Pantel S; Jiang G; Harrington WF; Lee Y; Goodale A; Lubonja R; Krill-Burger JM; Meyers RM; Tsherniak A; Root DE; Bradner JE; Golub TR; Roberts CW; Hahn WC; Weiss WA; Thiele CJ; Stegmaier K
J Clin Invest; 2018 Jan; 128(1):446-462. PubMed ID: 29202477
[TBL] [Abstract][Full Text] [Related]
2. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
[TBL] [Abstract][Full Text] [Related]
3. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry.
Durbin AD; Zimmerman MW; Dharia NV; Abraham BJ; Iniguez AB; Weichert-Leahey N; He S; Krill-Burger JM; Root DE; Vazquez F; Tsherniak A; Hahn WC; Golub TR; Young RA; Look AT; Stegmaier K
Nat Genet; 2018 Sep; 50(9):1240-1246. PubMed ID: 30127528
[TBL] [Abstract][Full Text] [Related]
4. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
[TBL] [Abstract][Full Text] [Related]
5. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.
Corvetta D; Chayka O; Gherardi S; D'Acunto CW; Cantilena S; Valli E; Piotrowska I; Perini G; Sala A
J Biol Chem; 2013 Mar; 288(12):8332-8341. PubMed ID: 23362253
[TBL] [Abstract][Full Text] [Related]
6. Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.
Torres J; Regan PL; Edo R; Leonhardt P; Jeng EI; Rappaport EF; Ikegaki N; Tang XX
Int J Oncol; 2010 Oct; 37(4):983-91. PubMed ID: 20811720
[TBL] [Abstract][Full Text] [Related]
7. MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21.
Liu L; Xu F; Chang CK; He Q; Wu LY; Zhang Z; Li X
Cell Death Dis; 2017 Oct; 8(10):e3126. PubMed ID: 29022893
[TBL] [Abstract][Full Text] [Related]
8. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
[TBL] [Abstract][Full Text] [Related]
9. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
10. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
[TBL] [Abstract][Full Text] [Related]
11. MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in Neuroblastoma.
Agarwal P; Glowacka A; Mahmoud L; Bazzar W; Larsson LG; Alzrigat M
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175848
[TBL] [Abstract][Full Text] [Related]
12. The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma.
Shaliman D; Takenobu H; Sugino RP; Ohira M; Kamijo T
Eur J Cell Biol; 2022; 101(3):151238. PubMed ID: 35636260
[TBL] [Abstract][Full Text] [Related]
13. Review: Targeting EZH2 in neuroblastoma.
Gao J; Fosbrook C; Gibson J; Underwood TJ; Gray JC; Walters ZS
Cancer Treat Rev; 2023 Sep; 119():102600. PubMed ID: 37467626
[TBL] [Abstract][Full Text] [Related]
14. TAp63 represses transcription of MYCN/NCYM gene and its high levels of expression are associated with favorable outcome in neuroblastoma.
Suenaga Y; Yamamoto M; Sakuma T; Sasada M; Fukai F; Ohira M; Yamaguchi Y; Yamamoto T; Ando K; Ozaki T; Nakagawara A
Biochem Biophys Res Commun; 2019 Oct; 518(2):311-318. PubMed ID: 31427086
[TBL] [Abstract][Full Text] [Related]
15. MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2.
Ding Y; Yang J; Ma Y; Yao T; Chen X; Ge S; Wang L; Fan X
J Exp Clin Cancer Res; 2019 Dec; 38(1):498. PubMed ID: 31856871
[TBL] [Abstract][Full Text] [Related]
16. p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas.
Dreidax D; Bannert S; Henrich KO; Schröder C; Bender S; Oakes CC; Lindner S; Schulte JH; Duffy D; Schwarzl T; Saadati M; Ehemann V; Benner A; Pfister S; Fischer M; Westermann F
Hum Mol Genet; 2014 Dec; 23(25):6826-37. PubMed ID: 25104850
[TBL] [Abstract][Full Text] [Related]
17. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
18. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
19. SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma.
Tan K; Mo J; Li M; Dong Y; Han Y; Sun X; Ma Y; Zhu K; Wu W; Lu L; Liu J; Zhao K; Zhang L; Tang Y; Lv Z
J Exp Clin Cancer Res; 2022 Dec; 41(1):352. PubMed ID: 36539767
[TBL] [Abstract][Full Text] [Related]
20. MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas.
Huang R; Cheung NK; Vider J; Cheung IY; Gerald WL; Tickoo SK; Holland EC; Blasberg RG
FASEB J; 2011 Dec; 25(12):4138-49. PubMed ID: 21856782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
